DOI 10.5414/CP201558

Int. Journal of Clinical Pharmacology and Therapeutics, Volume 49 - September (555 - 562)

Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey

G. Nakaji1, M. Fujihara1, M. Fukata1, S. Yasuda1, K. Odashiro1, T. Maruyama2, K. Akashi1 on Behalf of Fukuoka F-Scale Trial (FSCAT) Group
1 Department of Medicine, Biosystemic Science, 2 Institute of Health Science, Kyushu University, Fukuoka, Japan

Abstract

Background: Although gastroesophageal reflux disease (GERD) causes noncardiac chest pain mimicking angina pectoris, systemic studies surveying the effects of common cardiac drugs on symptomatic GERD are rare. Methods: To investigate the drugrelated GERD, this multicenter trial enrolled 201 consecutive cardiac outpatients (69.7 ± 10.5 y) after obtaining written informed consent. They were assessed using the Frequency Scale for Symptoms of GERD (F-scale) to screen for GERD with a cut-off value of 8.0. Clinical background was obtained from medical records. Gastric medicine was empirically administered at the discretion of the attending physician. F-scale score and incidence of GERD were analyzed individually in relation to background and prescription. Results: The average F-scale score did not correlate with gender, age or underlying diseases. F-scale score was elevated significantly (p = 0.006) by administration of calcium channel blockers to the patients treated with gastric medicine, suggesting that calcium channel blockers exacerbate the possibly preexisting GERD. Incidence of GERD within 2 months after starting warfarin tended to be greater than that at other durations (p = 0.087). Patients showing a high score (≥ 8.0) suggestive of GERD showed a correlation with the combined administration of calcium channel blockers (OR = 3.19; 95% CI of 1.01 – 10.11; p = 0.049) and warfarin (OR = 3.05; 95% CI of 1.00 – 9.27; p = 0.049) in the best logistic model. Conclusion: Although larger cohort is required, this survey demonstrates that the combination of calcium channel blockers and warfarin is an independent risk factor for GERD.

Author Details

Authors

  • G. Nakaji1
  • M. Fujihara1
  • M. Fukata1
  • S. Yasuda1
  • K. Odashiro1
  • T. Maruyama2
  • K. Akashi1 on Behalf of Fukuoka F-Scale Trial (FSCAT) Group

Departments

  • 1 Department of Medicine, Biosystemic Science,
  • 2 Institute of Health Science, Kyushu University, Fukuoka, Japan

Full Text

Add to Cart

Rights / Permissions

This section will be available soon


Shopping Overview
Type Qtty Price
Your basket is empty
View Cart